Additionally, the 36-month beta value for TVTX is 0.72. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 5 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for TVTX is 75.34M and currently, short sellers hold a 9.24% ratio of that float. The average trading volume of TVTX on October 14, 2024 was 1.70M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TVTX) stock’s latest price update
Travere Therapeutics Inc (NASDAQ: TVTX)’s stock price has plunge by -4.09relation to previous closing price of 17.11. Nevertheless, the company has seen a 7.75% surge in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-13 that NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. (“Travere” or “the Company”) (NASDAQ: TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/TVTX.
TVTX’s Market Performance
TVTX’s stock has risen by 7.75% in the past week, with a monthly rise of 30.24% and a quarterly rise of 67.28%. The volatility ratio for the week is 11.86% while the volatility levels for the last 30 days are 7.70% for Travere Therapeutics Inc The simple moving average for the last 20 days is 10.04% for TVTX stock, with a simple moving average of 85.22% for the last 200 days.
Analysts’ Opinion of TVTX
Many brokerage firms have already submitted their reports for TVTX stocks, with Guggenheim repeating the rating for TVTX by listing it as a “Buy.” The predicted price for TVTX in the upcoming period, according to Guggenheim is $25 based on the research report published on September 09, 2024 of the current year 2024.
Citigroup gave a rating of “Buy” to TVTX, setting the target price at $10 in the report published on December 05th of the previous year.
TVTX Trading at 39.44% from the 50-Day Moving Average
After a stumble in the market that brought TVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.77% of loss for the given period.
Volatility was left at 7.70%, however, over the last 30 days, the volatility rate increased by 11.86%, as shares surge +21.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +77.60% upper at present.
During the last 5 trading sessions, TVTX rose by +7.75%, which changed the moving average for the period of 200-days by +74.02% in comparison to the 20-day moving average, which settled at $14.91. In addition, Travere Therapeutics Inc saw 82.54% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TVTX starting from LYONS GARY A, who sale 40,000 shares at the price of $14.73 back on Oct 04 ’24. After this action, LYONS GARY A now owns 51,000 shares of Travere Therapeutics Inc, valued at $589,101 using the latest closing price.
GARY A LYONS, the Officer of Travere Therapeutics Inc, proposed sale 40,000 shares at $13.65 during a trade that took place back on Oct 04 ’24, which means that GARY A LYONS is holding shares at $546,000 based on the most recent closing price.
Stock Fundamentals for TVTX
Current profitability levels for the company are sitting at:
- -2.13 for the present operating margin
- 0.82 for the gross margin
The net margin for Travere Therapeutics Inc stands at -0.82. The total capital return value is set at -0.88. Equity return is now at value -582.60, with -59.56 for asset returns.
Based on Travere Therapeutics Inc (TVTX), the company’s capital structure generated 0.96 points at debt to capital in total, while cash flow to debt ratio is standing at -0.75. The debt to equity ratio resting at 25.3. The interest coverage ratio of the stock is -67.71.
Currently, EBITDA for the company is -331.81 million with net debt to EBITDA at -1.09. When we switch over and look at the enterprise to sales, we see a ratio of 9.15. The receivables turnover for the company is 6.52for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.04.
Conclusion
In conclusion, Travere Therapeutics Inc (TVTX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
